MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: STEMCELL Technologies, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

STEMCELL Technologies, Inc. Released New MesenCult™ Proliferation Kit with MesenPure™ - STEMCELL Technologies, Inc. has just released NEW MesenCult™ Proliferation Kit with MesenPure™ (Mouse), a novel cell culture medium to advance research on mouse mesenchymal stem and progenitor cells (MSCs) - Stemcell.com
STEMCELL Technologies, Inc. Released New MesenCult™ Proliferation Kit with MesenPure™

 

NewswireToday - /newswire/ - Vancouver, British Columbia, Canada, 2014/05/09 - STEMCELL Technologies, Inc. has just released NEW MesenCult™ Proliferation Kit with MesenPure™ (Mouse), a novel cell culture medium to advance research on mouse mesenchymal stem and progenitor cells (MSCs) - Stemcell.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

When added to MesenCult™ medium, MesenPure™ supplement enriches mouse bone marrow- or compact bone-derived MSC cultures by reducing the number of hematopoietic cells. Culturing with MesenPure™ eliminates the time-intensive serial passaging steps and frequent cell culture medium changes normally required to decrease the unwanted hematopoietic cell population typically present in MSC cultures. Cultures treated with MesenPure™ appear homogeneous and mostly devoid of hematopoietic cells as early as passage zero and also contain increased numbers of mesenchymal stem cells that display more robust differentiation.

This easy-to-use and versatile kit,“may save researchers from having to wait several weeks for homogeneous MSC cultures”, explains Dr. Arthur Sampaio, Senior Scientist at STEMCELL Technologies. “But, I think the greatest advantage to using MesenPure™ may be the ability to use lower-passage cultures. It has been shown that over time, extended passaging can bring about detrimental changes to MSCs, such as a loss of phenotype, senescence, and a decrease in the homing ability and differentiation potential of the cells. By using the MesenCult™ Proliferation Kit with MesenPure™, researchers will be able to study lower passage mouse MSCs, increasing their ability to evaluate the true potential of these cells.”

For more information or to request a free sample, please visit stemcell.com/freemesenpure.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: STEMCELL Technologies, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


STEMCELL Technologies, Inc. Released New MesenCult™ Proliferation Kit with MesenPure™

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Press Office - Stemcell.com 
1 800-667-0322 techsupport[.]stemcell.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any STEMCELL Technologies, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From STEMCELL Technologies, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®
Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs
Global Pharmaceutical Contract Manufacturing Organization Market to Reach 2.14 Billion by 2024 Finds Frost & Sullivan
Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)